This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.
Otherwise, you will be redirected to the institutional part of this website.
Thank you for your understanding.
CTI can suggest stratification based on matching score thresholds and also (optionally) suggest any molecular biomarkers (other than the targets/biomarkers of trial’s primary focus) that can influence the proposed therapy’s success or failure, alone or in various combinations, within a given population of patients. Based on the CTI analysis results and the needs of the Pharmaceutical Company involved, CureMatch can assist in refining clinical trial arms, comparison to other existing therapies, proposing markers for inclusion and exclusion criteria.
PDF results from patients’ molecular profiling tests performed using Next Generation Sequencing (NGS) of somatic DNA-level cancer biomarkers is a requirement. All know targets of the investigated therapy is a requirement. Additionally, proteomic and transcriptomic biomarkers wherever known can be provided for more comprehensive analysis.